Medicare is ending the shortcut that has let manufacturers of FDA-designated Breakthrough Devices collect extra hospital payments without first showing their products work better than what is already available.
The Centers for Medicare and Medicaid Services issued its fiscal year 2027 final hospital inpatient payment rule on July 31, finalizing the repeal of the alternative pathway to new technology add-on payments. The change applies to applications submitted on or after October 1, 2026, meaning the fiscal 2028 cycle onward. Technologies already approved for add-on payments, and applications already under review for fiscal 2027, remain eligible under the prior rules. Later applicants face the same three-part test as everyone else.
For patients, this is a payment policy change, not a coverage change. It does not remove any device from the market and does not by itself stop a hospital from using one. What it does is alter the financial calculation hospitals make when deciding whether to adopt an expensive new technology, which over time can influence where those technologies are available.
The Payment Program at the Center of the Change
New technology add-on payments, known as NTAP, were created in 2001. Medicare normally pays hospitals a fixed amount per case based on diagnosis and procedure. When a genuinely new technology costs more than that fixed payment covers, hospitals have a financial disincentive to use it. NTAP provides a temporary supplement, generally for two to three years, capped at 65% of the technology's cost or 65% of the amount by which the case cost exceeds the standard payment.
To qualify through the traditional route, a technology must be new, costly enough that the standard payment is inadequate, and demonstrate substantial clinical improvement over existing options.
Through the FY 2020 and FY 2021 hospital payment rules, CMS created an alternative pathway. Devices carrying FDA Breakthrough Device designation were deemed not substantially similar to existing technology and were exempted from the clinical improvement test. They still had to meet the cost criterion. A parallel exemption applied to certain antimicrobial products, and a comparable pathway exists on the outpatient side through the transitional pass-through program.
The Standard Manufacturers Now Have to Meet
Substantial clinical improvement is a comparative standard. CMS asks whether a technology represents an advance that substantially improves the diagnosis or treatment of Medicare beneficiaries relative to what was previously available.
The agency evaluates three things: whether the technology offers an option for patients who are unresponsive to or ineligible for current treatments, whether it can detect a condition earlier or detect one that is currently undetectable in a way that changes patient management, and whether it significantly improves clinical outcomes compared with existing services.
CMS has previously described qualifying evidence as showing reduced mortality, fewer hospitalizations or physician visits, or shorter recovery time compared with technologies previously available.
The Volume Data Behind the Decision
The alternative pathway changed application patterns substantially. As a legal analysis of the proposal by Ropes and Gray on the NTAP alternative pathway noted, CMS received 47 NTAP applications for fiscal year 2027, 32 through the alternative pathway and 15 through the traditional route. For fiscal year 2020, the year before the alternative pathway took effect, the agency received 18 applications in total.
CMS said in proposing the repeal that it had concerns about the limited evaluation process for these applications and about the value of the clinical improvement criterion being bypassed, and that holding all applicants to the same standard would better position the agency to make evidence-based decisions.
In the final rule, CMS estimated that add-on payments for new medical technologies will increase by roughly $779 million in fiscal 2027, driven largely by new approvals. Base inpatient payment rates rise 2.3%. The full rule is available in the Federal Register.
The Distinction Patients Should Understand
A Breakthrough Device designation is often reported as though it were a finding of superiority. It is not.
The FDA's Breakthrough Devices Program is designed to speed agency review of technologies that address life-threatening or irreversibly debilitating conditions. Designation gives a manufacturer more interaction with reviewers and priority handling. It is a process designation, awarded based on a device's potential, not a determination that the finished product outperforms existing options.
The FDA granted 164 breakthrough device designations in fiscal 2025. As of March 31, 2026, the agency had granted 1,284 designations in total, 1,264 through its device center and 20 through its biologics center. Only a fraction of designated devices ultimately reach the market.
Industry trade group AdvaMed opposed the repeal, saying the pathway had worked well and that it would be disappointing to see the progress rolled back. Reporting on the industry response to the proposed repeal noted that the alternative pathway was created during the first Trump administration.
Separately, CMS and FDA announced a coverage pathway in April intended to speed Medicare coverage decisions for eligible breakthrough devices, with the goal of issuing a proposed national coverage determination the same day a participating device receives FDA marketing authorization. That program addresses whether Medicare pays at all, a different question from how much a hospital receives.
Who Feels the Effect First
The immediate impact falls on device manufacturers, particularly smaller companies without the resources to run comparative outcome studies before launch.
For Medicare patients, effects are indirect and will emerge over years rather than months. Where a hospital concludes that a new device costs more than Medicare pays, adoption can slow, and slower adoption tends to show up first at hospitals with thinner margins.
Nothing here changes what an individual patient owes. Add-on payments flow to hospitals, not to patients, and are separate from deductibles, coinsurance, and Medicare Advantage plan rules.
If you are scheduled for a procedure involving a new device, it remains reasonable to ask your surgeon or cardiologist what evidence supports the device compared with standard alternatives, and to ask your hospital's financial counselor to confirm coverage before the procedure.
Frequently Asked Questions
What changed? CMS closed the alternative pathway that let FDA-designated Breakthrough Devices qualify for extra Medicare hospital payments without demonstrating substantial clinical improvement.
When does it take effect? It applies to NTAP applications submitted on or after October 1, 2026. Technologies already approved and applications under review for fiscal 2027 keep their eligibility under the old rules.
Does this affect my Medicare coverage? No. This is a hospital payment policy. It does not remove devices from the market or change what Medicare covers for an individual beneficiary.
Does a breakthrough designation mean a device is better? No. It is an FDA review designation intended to speed evaluation of promising technology. It is not a finding that the device outperforms existing options.
Will my out-of-pocket costs change? Add-on payments go to hospitals, not patients. Your deductible, coinsurance, and plan rules are unaffected by this change.
Who opposed the change? Device industry group AdvaMed argued the pathway had worked well and supported patient access to newly authorized technology.
What should I ask before a procedure? Ask what evidence compares the device with standard alternatives, and confirm coverage and expected costs with your hospital's financial counselor beforehand.
